Intra-arterial infusion of autologous bone marrow mononuclear cells combined with intravenous injection of cerebrolysin in the treatment of middle cerebral artery ischemic stroke: Case report

Le, Vien Chi; Nguyen, Ngoc Hoang; Le, Song

doi:10.1177/2050313x211002313

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Publisher confer some therapeutic effects, the effects were not significant [24][25][26]. Attempts have been made to develop novel MSC-based methods for the treatment of IS, such as genetically-modified MSCs, and use of preconditioning, electrical stimulation, and ultrasonic stimulation.…”

Section: Ivyspringmentioning

confidence: 99%

“…For example, in the harsh microenvironment of stroke (inflammation storm, oxidative stress), isolated MSCs gradually lose their homing ability to the lesion 23 . In clinical trials, although MSC therapy was shown to be safe and confer some therapeutic effects, the effects were not significant 24 - 26 . Attempts have been made to develop novel MSC-based methods for the treatment of IS, such as genetically-modified MSCs, and use of preconditioning, electrical stimulation, and ultrasonic stimulation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of ischemic stroke with modified mesenchymal stem cells

Chen

Zhou

2022

Int. J. Med. Sci.

View full text Add to dashboard Cite

Ischemic stroke is one of the leading causes of death and disability. Ischemia triggers a cascade of events leading to cell death and cerebral infarction. Mesenchymal stem cell (MSC) therapy is a promising treatment modality to promote the development of nerve and blood vessels and improve nerve function. However, MSCs have a limited therapeutic effect in the harsh microenvironment of ischemic brain tissue. Modified MSC therapy shows better therapeutic effect under different pathological conditions, and is expected to be translated into clinical practice. In this article, we review the latest advances in the development of modified MSCs for the treatment of cerebral ischemia. In particular, we summarize the targets involved in migration, homing, antioxidant stress, anti-inflammatory, nerve and vascular regeneration, providing new ideas for clinical transformation.

show abstract

Section: Ivyspringmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Treatment of ischemic stroke with modified mesenchymal stem cells

Chen

Zhou

2022

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…The results of Phase I and II clinical trials for the IA autologous bone marrow mononuclear cell infusion in stroke have already been published. The published trial outcome show the safety of autologous bone marrow mononuclear cells administration in sub-acute ischemic stroke [ 159 , 163 ], non-acute ischemic stroke [ 160 , 164 ], and moderate to severe acute middle cerebral artery strokes [ 159 , 165 , 166 ]. However, the analysis of the efficacy of stroke therapy with the IA injection of bone marrow mononuclear cells did not show prominent improvement in comparison with the placebo [ 159 , 163 ], although several trials have shown some improvement in patients receiving cell therapy [ 164 , 165 ].…”

Section: Clinical Trials Of the Intra-arterial Msc Infusion In Patients With Ischemic Strokementioning

confidence: 99%

“…However, the analysis of the efficacy of stroke therapy with the IA injection of bone marrow mononuclear cells did not show prominent improvement in comparison with the placebo [ 159 , 163 ], although several trials have shown some improvement in patients receiving cell therapy [ 164 , 165 ]. One study showed the safety and some efficacy of intra-arterial transplantation of allogeneic umbilical cord MSCs (UC-MSC) in patients with ischemic and hemorrhagic strokes [ 166 ]. Thus, so far, clinical trials failed to fully reveal the therapeutic potential of stem cells, as it has been done in animal models of stroke.…”

Section: Clinical Trials Of the Intra-arterial Msc Infusion In Patients With Ischemic Strokementioning

confidence: 99%

Cell Therapy of Stroke: Do the Intra-Arterially Transplanted Mesenchymal Stem Cells Cross the Blood–Brain Barrier?

Yarygin

Namestnikova

Sukhinich

et al. 2021

Cells

View full text Add to dashboard Cite

Animal model studies and first clinical trials have demonstrated the safety and efficacy of the mesenchymal stem cells’ (MSCs) transplantation in stroke. Intra-arterial (IA) administration looks especially promising, since it provides targeted cell delivery to the ischemic brain, is highly effective, and can be safe as long as the infusion is conducted appropriately. However, wider clinical application of the IA MSCs transplantation will only be possible after a better understanding of the mechanism of their therapeutic action is achieved. On the way to achieve this goal, the study of transplanted cells’ fate and their interactions with the blood–brain barrier (BBB) structures could be one of the key factors. In this review, we analyze the available data concerning one of the most important aspects of the transplanted MSCs’ action—the ability of cells to cross the blood–brain barrier (BBB) in vitro and in vivo after IA administration into animals with experimental stroke. The collected data show that some of the transplanted MSCs temporarily attach to the walls of the cerebral vessels and then return to the bloodstream or penetrate the BBB and either undergo homing in the perivascular space or penetrate deeper into the parenchyma. Transmigration across the BBB is not necessary for the induction of therapeutic effects, which can be incited through a paracrine mechanism even by cells located inside the blood vessels.

show abstract

Safety and Efficacy of Bone Marrow and Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Systematic Review

Afshar Hezarkhani,

Veysi,

Rahmani

et al. 2024

Cardiology in Review

View full text Add to dashboard Cite

Neurological diseases, including ischemic stroke, are considered a big challenge for public health due to their high prevalence and lack of definitive and effective treatments. Addressing these issues requires innovative therapeutic approaches and among the limited methods available, stem cells have shown promise in improving central nervous system repair by enhancing myelin regeneration and neuronal recovery. To advance this field of research, this systematic review aims to assess the safety and effectiveness of mesenchymal stem cells (MSCs) derived from both bone marrow and adipose tissue for the treatment of ischemic stroke. This study conducted a systematic review in the electronic databases PubMed, Scopus, Web of Science, Embase, ScienceDirect, and Google Scholar to assess the efficacy and safety of MSCs generated from bone marrow and adipose tissue for the treatment of ischemic stroke. It was extracted without a time limit until April 2023. The studies were then transferred to the information management program (EndNote) and duplicates were eliminated. The remaining studies were then examined using the entry and exit criteria and the 3 stages of primary, secondary, and qualitative evaluation, and finally, the results of the final studies were extracted. According to the initial search in the desired databases, 1028 possible related articles were identified and transferred to the information management software (EndNote). After removing 390 duplicate studies, 608 studies were excluded based on inclusion and exclusion criteria. Finally, 37 final studies were included in the systematic review process. Based on the investigations, it was evident that the administration of MSCs derived from both bone marrow and adipose tissue holds significant promise as an effective and safe treatment approach for ischemic stroke. The results consistently showed acceptable outcomes in the studies and this evidence can be recommended for the clinical application of this treatment. Also, the findings of this study report that the use of adipose tissue and bone marrow MSCs in the treatment of ischemic stroke can be used as a practical method.

show abstract

Intra-arterial infusion of autologous bone marrow mononuclear cells combined with intravenous injection of cerebrolysin in the treatment of middle cerebral artery ischemic stroke: Case report

Cited by 3 publications

References 21 publications

Treatment of ischemic stroke with modified mesenchymal stem cells

Treatment of ischemic stroke with modified mesenchymal stem cells

Cell Therapy of Stroke: Do the Intra-Arterially Transplanted Mesenchymal Stem Cells Cross the Blood–Brain Barrier?

Safety and Efficacy of Bone Marrow and Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Systematic Review

Contact Info

Product

Resources

About